Related Experiment Video

Updated: Jan 5, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.9K

[« ARNI » (Angiotensin Receptor-Neprilysin Inhibitor): when, for whom and how?]

Larissa Russo-Vorms1, Philippe Meyer2, Jean-Luc Reny3

  • 1Service de médecine interne générale, Département de médecine et service de médecine de premier recours, Département de médecine communautaire, HUG, 1211 Genève 14.

Revue Medicale Suisse
|October 17, 2019
PubMed

Insights

Sacubitril-valsartan, an Angiotensin Receptor-Neprilysin Inhibitor (ARNI), significantly reduces cardiovascular death and hospitalizations in heart failure patients with reduced ejection fraction. This review details its use and implications in chronic heart failure management.

Area of Science:

  • Cardiology
  • Pharmacology
  • Internal Medicine

Background:

  • Heart failure with reduced left ventricular ejection fraction (HFrEF) remains a leading cause of morbidity and mortality.
  • Current therapeutic strategies aim to reduce mortality and hospitalizations.
  • Angiotensin Receptor-Neprilysin Inhibitors (ARNIs) represent a novel therapeutic class.

Purpose of the Study:

  • To review the role and management of sacubitril-valsartan (an ARNI) in chronic heart failure.
  • To discuss the implications of the PARADIGM-HF trial findings.
  • To explore additional data and considerations for ARNI therapy.

Main Methods:

  • Review of the PARADIGM-HF trial data.
  • Analysis of sacubitril-valsartan's efficacy and safety profile.
  • Synthesis of current clinical guidelines and expert opinion.

Main Results:

  • Sacubitril-valsartan demonstrated superiority over enalapril in reducing cardiovascular mortality and heart failure hospitalizations in HFrEF patients.
  • The review covers initiation, use, and strategic placement of sacubitril-valsartan in heart failure management.
  • Additional data on hospitalized patients, preserved ejection fraction, and effects on renal/cognitive function are presented.

Conclusions:

  • Sacubitril-valsartan is a key therapeutic option for HFrEF management.
  • Careful initiation and monitoring are essential for optimal patient outcomes.
  • Further research is ongoing to define the full scope of ARNI benefits.

More Related Videos

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

18.4K
A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

5.5K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
867
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.3K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.2K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.2K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
419
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
349